Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 335
interventional 308
Observational 25
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 153
Drug|Other 18
Biological|Drug 15
Drug|placebo 15
Biological 12
Drug|Procedure 11
Other 9
Biological|Drug|Other 7
Biological|Other 7
Drug|Radiation 6
Procedure 6
Biological|Drug|Procedure 5
Biological|Other|Procedure 4
Diagnostic Test 4
Radiation 4
Genetic 3
Biological|Drug|Other|placebo 2
Biological|Drug|Radiation 2
Biological|Procedure 2
Combination Product 2
Device 2
Device|Drug 2
Drug|Other|Procedure 2
Drug|Other|Radiation 2
Drug|Procedure|Radiation 2
Behavioral|Dietary Supplement 1
Behavioral|Other 1
Behavioral|Other|Procedure 1
Biological|Device|Drug 1
Biological|Drug|Other|Procedure 1
Biological|Drug|placebo 1
Biological|Other|Radiation 1
Biological|Radiation 1
Combination Product|Drug 1
Dietary Supplement|Drug 1
Dietary Supplement|Drug|placebo 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 161
China 16
United States|Canada 7
Canada 6
France 6
Korea, Republic of 6
NA 6
United Kingdom 5
Denmark 4
Netherlands 4
Spain 4
Egypt 3
Germany 3
India 3
Italy 3
Taiwan 3
Belgium 2
Denmark|Sweden 2
Israel 2
Japan 2
United States|Canada|Japan|Korea, Republic of 2
United States|Israel 2
United States|Spain 2
Australia|New Zealand 1
Austria|Belgium|Denmark|Germany|Hungary|Israel|Italy|Netherlands|Poland|Spain|United Kingdom 1
Austria|Germany 1
Belgium|France 1
Belgium|France|Israel|Italy|Netherlands|Spain|Switzerland 1
Brazil|Canada|Finland|Netherlands|New Zealand|Norway|South Africa|United Kingdom 1
Finland 1
Finland|France|Germany 1
France|Netherlands|Spain|United Kingdom 1
Germany|Israel|Netherlands|Spain 1
Netherlands|Norway|Spain 1
Norway 1
Philippines|United States|Australia|Belgium|Canada|Denmark|France|Greece|Indonesia|Italy|Korea, Republic of|Poland|Russian Federation|Spain|Thailand|United Kingdom 1
Saudi Arabia 1
Spain|United States|France|Germany|Italy|United Kingdom 1
Switzerland 1
United States|Argentina|Belgium|Canada|France|Germany|Netherlands|Poland|United Kingdom 1
United States|Argentina|Belgium|Croatia|France|Spain 1
United States|Australia|Austria|Belgium|Canada|China|Czechia|Denmark|Finland|France|Germany|Hong Kong|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Portugal|Russian Federation|Singapore|Slovakia|Spain|Sweden|Switzerland|Taiwan|United Kingdom 1
United States|Australia|Austria|Canada|France|Greece|Indonesia|Italy|Korea, Republic of|Philippines|Singapore|Spain|Sweden|Switzerland|Thailand 1
United States|Australia|Belgium|Bosnia and Herzegovina|Brazil|Canada|Chile|China|Czechia|Estonia|Finland|Georgia|Greece|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Malaysia|Mexico|Spain|Netherlands|Poland|Portugal|Romania|Russian Federation|Serbia|Singapore|Slovenia|South Africa|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|China|Czechia|Finland|France|Germany|Greece|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Serbia|Spain|Switzerland|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|Denmark|France|Germany|Greece|Hungary|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Romania|Russian Federation|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Belgium|Canada|France|Germany|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Taiwan|Ukraine|United Kingdom 1
United States|Australia|Canada|Denmark|France|Germany|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Russian Federation|Spain|Taiwan|Turkey|United Kingdom 1
United States|Austria|Canada|Germany|Italy|Spain|Taiwan|United Kingdom 1
United States|Austria|France|Germany|Italy|Japan|Korea, Republic of|Spain 1
United States|Belarus|Belgium|France|Georgia|Italy|Korea, Republic of|Russian Federation|Spain|United Kingdom 1
United States|Belgium|Canada|France|Italy|Poland|Spain|United Kingdom 1
United States|Belgium|Denmark|France|Germany|Israel|Italy|Japan|Netherlands|Spain|United Kingdom 1
United States|Belgium|Finland|France|Italy|Japan|Spain 1
United States|Belgium|France|Germany|Hungary|Korea, Republic of|Poland|Spain|United Kingdom 1
United States|Belgium|France|Germany|Italy|Spain|United Kingdom 1
United States|Bulgaria|Korea, Republic of|Malaysia|Poland|Russian Federation|Ukraine 1
United States|Canada|Japan|Korea, Republic of|Puerto Rico 1
United States|Canada|Korea, Republic of 1
United States|Canada|Spain 1
United States|China|Korea, Republic of 1
United States|Czechia|France|Italy|Poland|Serbia|Spain 1
United States|France 1
United States|France|Australia|Austria|Belgium|Canada|Denmark|Germany|Hungary|Israel|Italy|Netherlands|Poland|Slovakia|Spain|United Kingdom 1
United States|France|Germany|Italy|Japan|Korea, Republic of|Netherlands|Spain 1
United States|France|Germany|Japan|Spain|United Kingdom 1
United States|France|Germany|Spain 1
United States|France|Greece|Korea, Republic of|Spain|United Kingdom 1
United States|France|Netherlands|Spain 1
United States|Hungary|Argentina|Australia|Canada|Denmark|France|Germany|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Taiwan|Turkey|United Kingdom 1
United States|Israel|Spain 1
United States|Italy 1
United States|Korea, Republic of|Spain|United Kingdom 1
United States|Korea, Republic of|Taiwan 1
United States|Puerto Rico 1
United States|Puerto Rico|South Africa 1
United States|South Africa 1

Sites per Study

Site_count Study_Count
1 122
2 19
3 18
4 7
5 9
6 7
7 5
8 8
9 6
10 4
11 6
12 2
13 1
14 3
15 4
16 2
17 1
18 2
19 2
20 4
21 2
22 4
23 1
24 2
25 2
26 4
27 1
28 3
29 3
30 1
31 1
32 1
33 1
34 1
35 2
39 3
40 1
42 1
50 1
55 1
59 1
60 1
61 1
62 1
64 1
75 1
76 2
80 1
95 1
96 1
112 1
121 1
124 1
128 1
134 1
136 1
141 1
142 1
143 1
161 1
163 1
165 1
172 1
184 1
188 1
225 1
234 1
272 1
315 1
354 1
358 1
395 1
508 1
573 1
632 1
687 1
815 1
873 1
938 1

Phase

Phase Study_Count
Phase 2 154
Phase 1 52
Phase 1/Phase 2 34
Phase 3 27
N/A 26
Early Phase 1 9
Phase 2/Phase 3 5
Phase 4 1

Number of Arms

Number_of_Arms Count_of_Studies
1 142
2 93
3 23
4 8
5 4
6 2
7 2
8 1
9 1
11 1
NA 31

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 6.00000 4.0000 4.00000 2.0000 2.00000 20.0 67.0000 50
1st Qu. 15.00000 55.2500 18.00000 39.2500 35.00000 34.0 273.0000 50
Median 18.00000 137.0000 30.00000 108.5000 50.00000 172.0 506.0000 50
Mean 21.11111 194.3077 53.05769 137.9412 86.93878 228.8 573.2222 50
3rd Qu. 20.00000 245.0000 53.25000 190.5000 83.00000 238.0 774.0000 50
Max. 54.00000 1050.0000 474.00000 557.0000 818.00000 680.0 1873.0000 50

Trial Group Type

group_type Group_Count
Experimental 404
Active Comparator 49
NA 31
Other 23
No Intervention 13
Placebo Comparator 13
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 160
Parallel Assignment 109
NA 22
Sequential Assignment 15
Crossover Assignment 2

Primary Purpose

primary_purpose Study_Count
Treatment 278
Diagnostic 13
Prevention 7
Other 5
Supportive Care 4
Basic Science 1

Observational Studies

Studies by Country

Country Study_Count
United States 10
Canada 4
China 3
Netherlands 2
United Kingdom 2
Argentina|Austria|Belgium|Brazil|Bulgaria|Colombia|Croatia|Egypt|France|Hungary|Israel|Italy|Lebanon|Lithuania|Mexico|Netherlands|Philippines|Poland|Portugal|Romania|Slovenia|Spain|United Arab Emirates|United Kingdom 1
Germany 1
Korea, Republic of 1
NA 1

Sites per Study

Site_count Study_Count
1 20
5 1
11 1
46 1
57 1
247 1

Enrollment Metrics

Measure Observational
Min 5.00
1st Qu 73.00
Median 250.00
Mean 923.44
3rd Qu 748.00
Max 11059.00

Observation Model

observational_model Study_Count
Cohort 19
Case-Control 2
Case-Only 2
Other 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 23
Retrospective 2

Registries

Studies by Country

Country Study_Count
China 1
Switzerland 1

Sites per Study

Site_count Study_Count
1 2

Enrollment Metrics

Measure Registries
Min 40
1st Qu 80
Median 120
Mean 120
3rd Qu 160
Max 200

Registry Model

observational_model Study_Count
Cohort 2

Time Perspective

time_perspective Study_Count
Prospective 2

Follow-up

target_duration Study_Count
3 Months 1
5 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT04092270 A Study Combining the M3814 Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer Patients https://ClinicalTrials.gov/show/NCT04092270 Recruiting National Cancer Institute (NCI) 2022-09-01
NCT03775265 Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer https://ClinicalTrials.gov/show/NCT03775265 Recruiting National Cancer Institute (NCI) 2025-06-01
NCT03737123 Trial of Atezolizumab Plus Chemotherapy After Progression on PD-1 or PD-L1 in Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03737123 Recruiting Hoosier Cancer Research Network 2021-01-31
NCT03502785 INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03502785 Active, not recruiting Inovio Pharmaceuticals 2021-07-31
NCT03410693 Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03410693 Active, not recruiting Bayer 2020-11-30
NCT03409458 A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab https://ClinicalTrials.gov/show/NCT03409458 Recruiting Phosplatin Therapeutics 2020-02-01
NCT03407976 Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies https://ClinicalTrials.gov/show/NCT03407976 Active, not recruiting University of Utah 2023-06-30
NCT03390595 Avelumab Plus Carboplatin-gemcitabine in Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03390595 Active, not recruiting Associació per a la Recerca Oncologica, Spain 2020-08-31
NCT03389438 Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03389438 Recruiting Beijing Huanxing Cancer Hospital 2020-01-31
NCT03375307 Olaparib in Treating Patients With Metastatic or Advanced Urothelial Cancer With DNA-Repair Defects https://ClinicalTrials.gov/show/NCT03375307 Recruiting National Cancer Institute (NCI) 2023-08-21
NCT03374488 Pembrolizumab + Epacadostat vs Pembrolizumab + Placebo in Recurrent or Progressive Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03374488 Active, not recruiting Incyte Corporation 2018-07-27
NCT03361865 Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307) https://ClinicalTrials.gov/show/NCT03361865 Active, not recruiting Incyte Corporation 2018-08-09
NCT03317158 ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT03317158 Recruiting Hoosier Cancer Research Network 2022-09-01
NCT03296306 Four Cycles Versus Six Cycles of Cisplatin-based Chemotherapy in Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03296306 Recruiting Asan Medical Center 2021-08-31
NCT03288545 A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer https://ClinicalTrials.gov/show/NCT03288545 Recruiting Astellas Pharma Inc 2023-07-31
NCT03287050 Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03287050 Active, not recruiting University of Michigan Rogel Cancer Center 2019-03-13
NCT03272217 Atezolizumab With Bevacizumab in Previously Untreated Metastatic/Unresectable Urothelial Cancer https://ClinicalTrials.gov/show/NCT03272217 Recruiting Hoosier Cancer Research Network 2020-06-30
NCT03266900 A Superiority Trial to Compare Re-resection of High-grade T1 Bladder Urothelial Carcinoma to no Re-resection for Improving Progression Free Survival https://ClinicalTrials.gov/show/NCT03266900 Recruiting University Health Network, Toronto 2020-12-31
NCT03265080 Expressing Personalized Tumor Antigens Study https://ClinicalTrials.gov/show/NCT03265080 Active, not recruiting Advaxis, Inc. 2020-05-31
NCT03263039 Biomarkers in Urothelial Cancer Patients Treated With Pembrolizumab https://ClinicalTrials.gov/show/NCT03263039 Recruiting Erasmus Medical Center 2019-08-21
NCT03240016 Abraxane With Anti-PD1/PDL1 in Patients With Advanced Urothelial Cancer https://ClinicalTrials.gov/show/NCT03240016 Recruiting University of Michigan Rogel Cancer Center 2021-10-01
NCT03236935 Phase Ib of L-NMMA and Pembrolizumab https://ClinicalTrials.gov/show/NCT03236935 Recruiting The Methodist Hospital System 2020-01-01
NCT03230201 Lymph Node Dissection in High-risk UTUC(Upper Tract Urothelial Carcinoma) https://ClinicalTrials.gov/show/NCT03230201 Recruiting Peking University First Hospital 2021-01-01
NCT03228667 QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer https://ClinicalTrials.gov/show/NCT03228667 Recruiting Altor BioScience 2021-06-30
NCT03219775 Tailored ImmunoTherapy Approach With Nivolumab in Subjects With Metastatic or Advanced Transitional Cell Carcinoma https://ClinicalTrials.gov/show/NCT03219775 Recruiting AIO-Studien-gGmbH 2020-12-31
NCT03219333 A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer https://ClinicalTrials.gov/show/NCT03219333 Active, not recruiting Astellas Pharma Inc 2020-11-30
NCT03209206 The Effectiveness and Safety of Intravesical Docetaxel Instillation for Prevent Bladder Recurrence https://ClinicalTrials.gov/show/NCT03209206 Recruiting Seoul National University Hospital 2020-06-19
NCT03185468 Intervention of Bladder Cancer by CAR-T https://ClinicalTrials.gov/show/NCT03185468 Recruiting Shenzhen Geno-Immune Medical Institute 2019-12-31
NCT03171493 Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy https://ClinicalTrials.gov/show/NCT03171493 Recruiting Vyriad, Inc. 2020-12-31
NCT03115801 A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers https://ClinicalTrials.gov/show/NCT03115801 Active, not recruiting Weill Medical College of Cornell University 2020-12-31
NCT03113266 Safety and Efficacy of Toripalimab for Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03113266 Recruiting Shanghai Junshi Bioscience Co., Ltd. 2020-02-29
NCT03093922 A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer https://ClinicalTrials.gov/show/NCT03093922 Recruiting Memorial Sloan Kettering Cancer Center 2021-03-31
NCT03091660 S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer https://ClinicalTrials.gov/show/NCT03091660 Recruiting Southwest Oncology Group 2022-02-15
NCT03081858 Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer https://ClinicalTrials.gov/show/NCT03081858 Recruiting Lipac Oncology LLC 2020-05-31
NCT03070990 A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03070990 Completed Astellas Pharma Inc 2019-02-25
NCT03047213 Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations https://ClinicalTrials.gov/show/NCT03047213 Recruiting National Cancer Institute (NCI) 2022-10-01
NCT03039413 Copper Cu-64 TP3805 PET/CT in Imaging Patients With Urothelial Cancer Undergoing Surgery or Biopsy https://ClinicalTrials.gov/show/NCT03039413 Active, not recruiting Thomas Jefferson University 2021-03-15
NCT03030157 Single Versus Long-term Intravesical Instillation Chemotherapy for Recurrence After Nephroureterectomy for Upper Tract Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03030157 Recruiting RenJi Hospital 2020-01-31
NCT02994758 Development of Diagnostics and Treatment of Urological Cancers https://ClinicalTrials.gov/show/NCT02994758 Recruiting Helsinki University Central Hospital 2020-12-31
NCT02989584 A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer https://ClinicalTrials.gov/show/NCT02989584 Recruiting Memorial Sloan Kettering Cancer Center 2021-12-31
NCT02989064 MAGE-A10ᶜ⁷⁹⁶T for Urothelial Cancer, Melanoma or Head and Neck Cancers https://ClinicalTrials.gov/show/NCT02989064 Active, not recruiting Adaptimmune 2019-12-18
NCT02986867 SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma https://ClinicalTrials.gov/show/NCT02986867 Completed University of Texas Southwestern Medical Center 2018-03-07
NCT02983045 A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors ( PIVOT-02 ) https://ClinicalTrials.gov/show/NCT02983045 Active, not recruiting Nektar Therapeutics 2020-12-31
NCT02969083 Feasibility of Neo-adjuvant Versus Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT02969083 Recruiting The European Uro-Oncology Group 2020-10-31
NCT02968732 Cystoscopic Evaluation Predicting pT0 Urothelial Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT02968732 Active, not recruiting Fox Chase Cancer Center 2019-08-19
NCT02951325 Bladder Cancer Adjuvant Radiotherapy Trial https://ClinicalTrials.gov/show/NCT02951325 Recruiting Tata Memorial Centre 2023-04-13
NCT02923739 Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02923739 Active, not recruiting M.D. Anderson Cancer Center 2025-05-31
NCT02923557 Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Nephroureterectomy for Primary Upper Tract Urothelial Carcinoma Patients https://ClinicalTrials.gov/show/NCT02923557 Recruiting Peking University First Hospital 2021-11-30
NCT02901548 Phase 2 Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refactory Urothelial Carcinoma in Situ of the Bladder https://ClinicalTrials.gov/show/NCT02901548 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2020-12-31
NCT02897765 A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer https://ClinicalTrials.gov/show/NCT02897765 Completed Neon Therapeutics, Inc. 2020-02-29
NCT02876861 Neoadjuvant Chemotherapy Versus Surgery Alone in Patients With High-Grade UTUC https://ClinicalTrials.gov/show/NCT02876861 Recruiting Xiangya Hospital of Central South University 2020-08-31
NCT02872714 A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Urothelial Carcinoma - (FIGHT-201) https://ClinicalTrials.gov/show/NCT02872714 Recruiting Incyte Corporation 2020-08-31
NCT02853305 Study of Pembrolizumab With or Without Platinum-based Combination Chemotherapy Versus Chemotherapy Alone in Urothelial Carcinoma (MK-3475-361/KEYNOTE-361) https://ClinicalTrials.gov/show/NCT02853305 Active, not recruiting Merck Sharp & Dohme Corp. 2020-05-21
NCT02845323 Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT02845323 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2020-09-30
NCT02844816 Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer https://ClinicalTrials.gov/show/NCT02844816 Active, not recruiting National Cancer Institute (NCI) 2021-04-01
NCT02812420 Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery https://ClinicalTrials.gov/show/NCT02812420 Active, not recruiting M.D. Anderson Cancer Center 2020-03-31
NCT02808143 Pembrolizumab and BCG Solution in Treating Patients With Recurrent Non-Muscle-Invasive Bladder Cancer https://ClinicalTrials.gov/show/NCT02808143 Recruiting Northwestern University 2020-01-31
NCT02807636 Study of Atezolizumab as Monotherapy and in Combination With Platinum-Based Chemotherapy in Participants With Untreated Locally Advanced or Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT02807636 Active, not recruiting Hoffmann-La Roche 2021-06-11
NCT02793128 The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study https://ClinicalTrials.gov/show/NCT02793128 Active, not recruiting UroGen Pharma Ltd. 2019-04-05
NCT02788201 Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT02788201 Completed National Institutes of Health Clinical Center (CC) 2019-10-23
NCT02767921 sEphB4-HSA Before Surgery in Treating Patients With Bladder Cancer, Prostate Cancer, or Kidney Cancer https://ClinicalTrials.gov/show/NCT02767921 Recruiting University of Southern California 2020-08-02
NCT02740426 Prophylactic Intravesical Chemotherapy to Prevent Bladder Recurrence After Diagnostic Ureteroscopy for Primary Upper Tract Urothelial Carcinoma Patients https://ClinicalTrials.gov/show/NCT02740426 Recruiting Peking University First Hospital 2021-05-31
NCT02717156 Combination Therapy With Pembrolizumab and sEphB4-HSA in Previously Treated Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT02717156 Recruiting University of Southern California 2020-11-21
NCT02710734 Risk Enabled Therapy After Initiating Neoadjuvant Chemotherapy for Bladder Cancer (RETAIN) https://ClinicalTrials.gov/show/NCT02710734 Recruiting Fox Chase Cancer Center 2021-04-30
NCT02693717 Pemetrexed Disodium in Treating Patients With Previously Treated Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT02693717 Active, not recruiting M.D. Anderson Cancer Center 2020-05-31
NCT02665039 A Trial With Vinflunine in Patients With Metastatic Bladder Cancer and Impaired Renal Function https://ClinicalTrials.gov/show/NCT02665039 Completed Karolinska University Hospital 2018-09-30
NCT02662309 Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT02662309 Active, not recruiting Queen Mary University of London 2018-07-31
NCT02657486 BGJ398 in Non-Muscle-Invasive Urothelial Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT02657486 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-01-31
NCT02643043 UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch https://ClinicalTrials.gov/show/NCT02643043 Active, not recruiting Hoosier Cancer Research Network 2020-01-31
NCT02608125 A Dose Escalation Study in Solid Tumors and a Dose Expansion Study of PRN1371 in Adult Patients With Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT02608125 Active, not recruiting Principia Biopharma Inc. 2020-12-31
NCT02607709 Lymphadenectomy in Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT02607709 Recruiting Zealand University Hospital 2022-01-31
NCT02585362 Whey Protein Supplement in Combination With Physical Exercise and Nutrition Program https://ClinicalTrials.gov/show/NCT02585362 Completed Kantonsspital Winterthur KSW 2018-10-31
NCT03138889 A Study of a CD122-Biased Cytokine (NKTR-214) in Combination With Anti-PD-1 (Pembrolizumab) in Patients With Select Advanced or Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03138889 Recruiting Nektar Therapeutics 2021-06-30
NCT02769962 Trial of CRLX101, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer https://ClinicalTrials.gov/show/NCT02769962 Recruiting National Institutes of Health Clinical Center (CC) 2023-07-01
NCT02647112 Utility of Bladder EpiCheck for Detection of Recurrent Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT02647112 Active, not recruiting Nucleix Ltd. 2020-12-31
NCT02573259 A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors https://ClinicalTrials.gov/show/NCT02573259 Active, not recruiting Pfizer 2020-11-02
NCT02502266 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02502266 Recruiting National Cancer Institute (NCI) 2023-06-30
NCT02443324 A Study of Ramucirumab Plus Pembrolizumab in Participants With Gastric or GEJ Adenocarcinoma, NSCLC, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer https://ClinicalTrials.gov/show/NCT02443324 Active, not recruiting Eli Lilly and Company 2018-08-31
NCT02567409 Cisplatin and Gemcitabine Hydrochloride With or Without ATR Kinase Inhibitor M6620 in Treating Patients With Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT02567409 Active, not recruiting National Cancer Institute (NCI) 2020-08-31
NCT03988309 The Cxbladder Hematuria Clinical Utility Study https://ClinicalTrials.gov/show/NCT03988309 Recruiting Pacific Edge Limited 2020-07-31
NCT03547973 Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT03547973 Recruiting Immunomedics, Inc. 2021-09-30
NCT03397394 Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03397394 Completed Clovis Oncology, Inc. 2019-12-12
NCT03387761 Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapy https://ClinicalTrials.gov/show/NCT03387761 Recruiting The Netherlands Cancer Institute 2021-01-01
NCT02535650 Study of Tipifarnib in Patients With Previously-Treated, Advanced, HRAS Mutant Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT02535650 Recruiting Samsung Medical Center 2019-12-31
NCT02500121 Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer https://ClinicalTrials.gov/show/NCT02500121 Active, not recruiting Hoosier Cancer Research Network 2019-07-01
NCT02496208 Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors https://ClinicalTrials.gov/show/NCT02496208 Recruiting National Cancer Institute (NCI) 2020-09-30
NCT02482168 Study of the CD40 Agonistic Monoclonal Antibody APX005M https://ClinicalTrials.gov/show/NCT02482168 Completed Apexigen, Inc. 2018-06-13
NCT02462239 Impact of Positron Emission Tomography (PET) Imaging in Muscle-invasive Urothelial Carcinoma of the Bladder Staging https://ClinicalTrials.gov/show/NCT02462239 Recruiting Ontario Clinical Oncology Group (OCOG) 2020-04-30
NCT02451423 Neoadjuvant Atezolizumab in Localized Bladder Cancer https://ClinicalTrials.gov/show/NCT02451423 Recruiting University of California, San Francisco 2020-12-31
NCT02450331 A Study of Atezolizumab Versus Observation as Adjuvant Therapy in Participants With High-Risk Muscle-Invasive Urothelial Carcinoma (UC) After Surgical Resection https://ClinicalTrials.gov/show/NCT02450331 Active, not recruiting Hoffmann-La Roche 2019-11-30
NCT02446600 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02446600 Active, not recruiting National Cancer Institute (NCI) 2020-02-23
NCT02438865 Prophylactic Intravesical Chemotherapy After Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: a Randomized Controlled Trial Between Single Postoperative Dose Versus Maintenance Therapy. https://ClinicalTrials.gov/show/NCT02438865 Completed Mansoura University 2018-05-01
NCT02437370 Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer https://ClinicalTrials.gov/show/NCT02437370 Recruiting University of California, Davis 2020-06-30
NCT02426125 A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer https://ClinicalTrials.gov/show/NCT02426125 Active, not recruiting Eli Lilly and Company 2017-04-21
NCT02412670 Chemotherapy Before Surgery in Treating Patients With High Grade Upper Urinary Tract Cancer https://ClinicalTrials.gov/show/NCT02412670 Active, not recruiting Eastern Cooperative Oncology Group 2020-02-29
NCT02364713 MV-NIS or Investigator’s Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer https://ClinicalTrials.gov/show/NCT02364713 Recruiting Mayo Clinic 2027-03-17
NCT02351739 Study of the Combination of ACP-196 and Pembrolizumab in Subjects With Platinum Resistant Urothelial Bladder Cancer https://ClinicalTrials.gov/show/NCT02351739 Completed Acerta Pharma BV 2018-02-28
NCT02326909 Diagnostic Accuracy of Optical Coherence Tomography in Upper Urinary Tract Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT02326909 Completed Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 2014-12-31
NCT02318329 Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT02318329 Completed Five Prime Therapeutics, Inc. 2019-02-28
NCT02300610 Enzalutamide in Combination With Gemcitabine and Cisplatin in Bladder Cancer https://ClinicalTrials.gov/show/NCT02300610 Completed H. Lee Moffitt Cancer Center and Research Institute 2017-08-07
NCT02236195 Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes https://ClinicalTrials.gov/show/NCT02236195 Completed Mirati Therapeutics Inc. 2016-04-30
NCT02202772 Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT02202772 Active, not recruiting Columbia University 2018-06-01
NCT02160600 Dual Energy CT vs Standard Triple Phase CT-A Randomised Control Trial https://ClinicalTrials.gov/show/NCT02160600 Completed All India Institute of Medical Sciences, New Delhi 2016-12-31
NCT02111941 Vaccine Therapy in Treating Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Following Surgery and Chemotherapy https://ClinicalTrials.gov/show/NCT02111941 Active, not recruiting Mayo Clinic 2017-08-18
NCT02109328 Alisertib in Chemotherapy-pretreated Urothelial Cancer https://ClinicalTrials.gov/show/NCT02109328 Completed Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 2015-07-02
NCT02101931 A Laser Detection for Bladder Cancer by (Photodynamic) Spectra of Urine https://ClinicalTrials.gov/show/NCT02101931 Completed Princess Al-Johara Al-Ibrahim Cancer Research Center 2016-03-31
NCT02068794 MV-NIS Infected Mesenchymal Stem Cells in Treating Patients With Recurrent Ovarian Cancer https://ClinicalTrials.gov/show/NCT02068794 Recruiting Mayo Clinic 2021-03-10
NCT02020707 Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery or Gynecological Cancers https://ClinicalTrials.gov/show/NCT02020707 Recruiting Mayo Clinic 2020-10-03
NCT04383938 Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies https://ClinicalTrials.gov/show/NCT04383938 Recruiting Aprea Therapeutics 2021-12-31
NCT03854474 Tazemetostat and Pembrolizumab in Treating Patients With Locally Advanced or Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03854474 Recruiting National Cancer Institute (NCI) 2020-06-30
NCT02014337 Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors https://ClinicalTrials.gov/show/NCT02014337 Completed Corcept Therapeutics 2017-12-31
NCT01993979 A Phase III Randomised Trial of Peri-Operative Chemotherapy Versus sUrveillance in Upper Tract Urothelial Cancer (POUT) https://ClinicalTrials.gov/show/NCT01993979 Active, not recruiting Institute of Cancer Research, United Kingdom 2018-11-07
NCT01954173 Adjuvant Radiation for High Risk Bladder Cancer https://ClinicalTrials.gov/show/NCT01954173 Recruiting Emory University 2030-07-31
NCT01878188 Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma https://ClinicalTrials.gov/show/NCT01878188 Completed Anchiano Therapeutics Israel Ltd. 2015-10-31
NCT01846520 Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers https://ClinicalTrials.gov/show/NCT01846520 Completed City of Hope Medical Center 2019-05-23
NCT01844947 Phase I Study With Sorafenib in Addition to Vinflunine in Metastatic Transitional Cell Carcinoma of the Urothelial Tract https://ClinicalTrials.gov/show/NCT01844947 Completed Karolinska University Hospital 2017-10-18
NCT01824329 Prostate Capsule Sparing Cystectomy and Nerve-sparing Radical Cystoprostatectomy in Men With Bladder Cancer https://ClinicalTrials.gov/show/NCT01824329 Completed University of Michigan 2014-08-31
NCT01801137 The Efficacy of RAD 001 as Second Line Therapy in Patients With Transitional Cell Carcinoma TCC of the Urothelium https://ClinicalTrials.gov/show/NCT01801137 Completed Hopital Foch 2014-10-31
NCT01780545 Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer https://ClinicalTrials.gov/show/NCT01780545 Completed Hoosier Cancer Research Network 2017-10-31
NCT01688999 Cabozantinib for Advanced Urothelial Cancer https://ClinicalTrials.gov/show/NCT01688999 Active, not recruiting National Institutes of Health Clinical Center (CC) 2017-12-11
NCT01668459 Treatment of Locally Advanced or Metastatic Transitional Cell Carcinoma With Cabazitaxel https://ClinicalTrials.gov/show/NCT01668459 Completed University Hospital Birmingham NHS Foundation Trust 2017-11-30
NCT01642082 Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer https://ClinicalTrials.gov/show/NCT01642082 Completed Gynecologic Oncology Group 2016-01-31
NCT01606345 Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT01606345 Completed H. Lee Moffitt Cancer Center and Research Institute 2016-04-30
NCT01600339 A Trial of Cabazitaxel for Advanced Transitional Cell Carcinoma (TCC) https://ClinicalTrials.gov/show/NCT01600339 Completed Rambam Health Care Campus 2015-01-31
NCT01599013 JAVLOR Association Study in CDDP-unfit Patients With Advanced Transitional Cell Carcinoma: Gemcitabine Versus Carboplatin https://ClinicalTrials.gov/show/NCT01599013 Completed Pierre Fabre Medicament 2013-10-31
NCT04322643 Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT04322643 Recruiting Case Comprehensive Cancer Center 2021-05-31
NCT01551030 Buparlisib in Metastatic Transitional Cell Carcinoma of the Urothelium https://ClinicalTrials.gov/show/NCT01551030 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-03-31
NCT01529411 Clinical Trial With Vinflunine as Maintenance Therapy in Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT01529411 Completed Spanish Oncology Genito-Urinary Group 2013-02-28
NCT01524991 First-Line Gemcitabine, Cisplatin + Ipilimumab for Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT01524991 Completed Hoosier Cancer Research Network 2017-07-15
NCT01520038 Adjuvant Proton Therapy or IMRT for the Treatment of Bladder Cancer https://ClinicalTrials.gov/show/NCT01520038 Completed Abramson Cancer Center of the University of Pennsylvania 2013-12-31
NCT01495676 A Phase II Trial Evaluating an Organ-conserving Strategy by Radiochemotherapy for Muscle-infiltrative Bladder Cancer https://ClinicalTrials.gov/show/NCT01495676 Recruiting Institut du Cancer de Montpellier - Val d’Aurelle 2022-09-30
NCT01490437 Pemetrexed and Cisplatin in Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT01490437 Completed Asan Medical Center 2013-12-31
NCT01478685 A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01478685 Completed Celgene 2015-11-17
NCT01440998 Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer https://ClinicalTrials.gov/show/NCT01440998 Completed National Cancer Institute (NCI) 2015-12-31
NCT01437488 Cabazitaxel in Patients With Urothelial Carcinoma Who Have Disease Progression Following Platinum-Based Chemotherapy https://ClinicalTrials.gov/show/NCT01437488 Completed Thomas Jefferson University 2014-08-04
NCT01328574 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT01328574 Completed National Institutes of Health Clinical Center (CC) 2014-05-31
NCT04341740 Investigating Marrow Infiltrating Lymphocytes in Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT04341740 Recruiting University of Oklahoma 2021-07-31
NCT04264936 A Study of RC48-ADC(Antibody Drug Conjugate) and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT04264936 Recruiting Beijing Cancer Hospital 2021-01-30
NCT04200963 IK-175 in Patients With Advanced or Metastatic Solid Tumors and Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT04200963 Recruiting Ikena Oncology 2022-09-30
NCT04198766 Study of INBRX-106 in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) https://ClinicalTrials.gov/show/NCT04198766 Recruiting Inhibrx, Inc. 2022-12-02
NCT04197986 Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations https://ClinicalTrials.gov/show/NCT04197986 Recruiting QED Therapeutics, Inc. 2024-01-31
NCT04197089 Biological Effect of Vitamin D in Patients With Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT04197089 Recruiting Germans Trias i Pujol Hospital 2021-07-31
NCT04173338 Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma https://ClinicalTrials.gov/show/NCT04173338 Recruiting Augusta University 2020-11-30
NCT04167631 Can VI-RADS/ADC Accurately Stage Bladder Cancer?? https://ClinicalTrials.gov/show/NCT04167631 Active, not recruiting Mansoura University 2020-06-01
NCT04113603 Diagnostic Values of Urothelial Carcinomas: Single-bolus Versus Split-bolus Computed Tomography Urography https://ClinicalTrials.gov/show/NCT04113603 Recruiting Chang Gung Memorial Hospital 2021-07-31
NCT04099589 Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT04099589 Recruiting Cancer Institute and Hospital, Chinese Academy of Medical Sciences 2022-10-01
NCT04077359 Prospective Trial for Examining Hematuria Using Computed Tomography https://ClinicalTrials.gov/show/NCT04077359 Recruiting Oslo University Hospital 2021-09-01
NCT04066595 Cabozantinib in Patients With Locally Advanced or Metastatic Urothelial Cell Carcinoma. https://ClinicalTrials.gov/show/NCT04066595 Recruiting Johannes Gutenberg University Mainz 2023-09-30
NCT04047693 Neoadjuvant Dose Dense MVAC in MIBC and Locally Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT04047693 Recruiting Pusan National University Yangsan Hospital 2021-12-31
NCT04045613 Derazantinib and Atezolizumab in Patients With Urothelial Cancer https://ClinicalTrials.gov/show/NCT04045613 Recruiting Basilea Pharmaceutica 2022-04-30
NCT04018053 18Fluorine-Fluciclovine PET/CT for Staging Muscle Invasive Bladder Cancer Preceding Radical Cystectomy https://ClinicalTrials.gov/show/NCT04018053 Recruiting Dana-Farber Cancer Institute 2021-12-31
NCT04007744 Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04007744 Recruiting Mayo Clinic 2021-07-31
NCT04004442 Avelumab in Combination With AVB-S6-500 in Patients With Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT04004442 Recruiting University of Oklahoma 2021-07-31
NCT03992131 A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR) https://ClinicalTrials.gov/show/NCT03992131 Recruiting Clovis Oncology, Inc. 2023-10-31
NCT03980041 Study to Evaluate the Efficacy/Safety of IPI-549 in Combination With Nivolumab in Patients With Advanced Urothelial Carcinoma (MARIO-275) https://ClinicalTrials.gov/show/NCT03980041 Recruiting Infinity Pharmaceuticals, Inc. 2020-11-30
NCT03967977 Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03967977 Recruiting BeiGene 2022-07-31
NCT03945084 Maintenance With Niraparib In Patients With Advanced Urothelial Cancer After 1st-line Platinum-based Chemotherapy https://ClinicalTrials.gov/show/NCT03945084 Recruiting University of Turin, Italy 2021-12-31
NCT03917381 GEN1046 Safety Trial in Patients With Malignant Solid Tumors https://ClinicalTrials.gov/show/NCT03917381 Recruiting Genmab 2021-10-31
NCT03915405 KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer https://ClinicalTrials.gov/show/NCT03915405 Recruiting Kyowa Kirin Pharmaceutical Development, Inc. 2021-12-31
NCT03914794 A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors https://ClinicalTrials.gov/show/NCT03914794 Recruiting Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 2022-05-31
NCT03912818 Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer https://ClinicalTrials.gov/show/NCT03912818 Recruiting Stanford University 2022-02-13
NCT03869190 A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-based Treatment Combinations in Patients With Locally Advanced or Metastatic Urothelial Carcinoma After Failure With Platinum-Containing Chemotherapy https://ClinicalTrials.gov/show/NCT03869190 Recruiting Hoffmann-La Roche 2020-09-30
NCT03854721 A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer https://ClinicalTrials.gov/show/NCT03854721 Recruiting Vaxiion Therapeutics 2020-11-30
NCT03827837 Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors https://ClinicalTrials.gov/show/NCT03827837 Recruiting Jiangsu HengRui Medicine Co., Ltd. 2020-06-30
NCT03809624 Study of INBRX-105 in Patients With Solid Tumors https://ClinicalTrials.gov/show/NCT03809624 Recruiting Inhibrx, Inc. 2021-07-31
NCT03809013 A Open-label, Single-arm, Multicenter, Phase II Study of RC48-ADC to Evaluate the Efficacy and Safety of Subjects With HER2 Overexpressing Locally Advanced or Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT03809013 Recruiting RemeGen 2021-10-31
NCT03758781 IRX-2 Regimen Combined With Nivolumab in Recurrent/Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03758781 Recruiting H. Lee Moffitt Cancer Center and Research Institute 2021-02-28
NCT03745911 Paclitaxel and TAK-228 in Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03745911 Recruiting Associació per a la Recerca Oncologica, Spain 2020-11-30
NCT03744793 Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT03744793 Recruiting M.D. Anderson Cancer Center 2021-01-31
NCT03735680 A Study to Evaluate ONM-100, an Intraoperative Fluorescence Imaging Agent for the Detection of Cancer https://ClinicalTrials.gov/show/NCT03735680 Recruiting OncoNano Medicine, Inc. 2020-09-30
NCT03689192 Arginase-1 Peptide Vaccine in Patients With Metastatic Solid Tumors https://ClinicalTrials.gov/show/NCT03689192 Recruiting Herlev Hospital 2020-12-31
NCT03682289 Phase II Trial of AZD6738 Alone and in Combination With Olaparib https://ClinicalTrials.gov/show/NCT03682289 Recruiting University of California, San Francisco 2021-03-19
NCT03676946 A Clinical Study of PD-L1 Antibody ZKAB001(Drug Code) in Locally Advanced and Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03676946 Recruiting Lee’s Pharmaceutical Limited 2020-02-14
NCT03658304 Trial of Mitomycin C During Nephroureterectomy for Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03658304 Recruiting University of Florida 2025-12-31
NCT03641287 The Effects of Moderate Exercise on Distress, Quality of Life, and Biomarkers of Angiogenesis and Chronic Stress in Ovarian Cancer Survivors https://ClinicalTrials.gov/show/NCT03641287 Recruiting University of Washington 2020-10-24
NCT03639714 A Study of a Personalized Neoantigen Cancer Vaccine https://ClinicalTrials.gov/show/NCT03639714 Recruiting Gritstone Oncology, Inc. 2022-07-31
NCT03633110 Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine https://ClinicalTrials.gov/show/NCT03633110 Active, not recruiting Genocea Biosciences, Inc. 2022-12-31
NCT03617913 Avelumab in Combination With Fluorouracil and Mitomycin or Cisplatin and Radiation Therapy in Treating Participants With Muscle-Invasive Bladder Cancer https://ClinicalTrials.gov/show/NCT03617913 Active, not recruiting Mayo Clinic 2019-11-14
NCT03617003 Treatment of Tumors in the Urinary Collecting System of the Kidney or Ureter Using a Light Activated Drug (WST11) https://ClinicalTrials.gov/show/NCT03617003 Recruiting Memorial Sloan Kettering Cancer Center 2021-08-31
NCT03609216 Dose Dense Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations https://ClinicalTrials.gov/show/NCT03609216 Recruiting Alliance for Clinical Trials in Oncology 2027-02-28
NCT03606174 Study of Sitravatinib and Nivolumab in Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03606174 Recruiting Mirati Therapeutics Inc. 2021-01-31
NCT03601455 Radiation Therapy and Durvalumab With or Without Tremelimumab in Treating Participants With Unresectable, Locally Advanced, or Metastatic Bladder Cancer https://ClinicalTrials.gov/show/NCT03601455 Recruiting Jonsson Comprehensive Cancer Center 2021-11-01
NCT03584659 Patient-reported Outcomes in Bladder Cancer https://ClinicalTrials.gov/show/NCT03584659 Recruiting Rigshospitalet, Denmark 2020-03-31
NCT03582475 Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate https://ClinicalTrials.gov/show/NCT03582475 Recruiting Jonsson Comprehensive Cancer Center 2020-09-01
NCT03575013 A Combination of Avelumab and Taxane (AVETAX) for Urothelial Cancer https://ClinicalTrials.gov/show/NCT03575013 Recruiting University of Iowa 2021-02-28
NCT03558503 The Efficacy and Safety of UGN-102 as a Primary Chemoablative Therapy in Patients With LG NMIBC at Intermediate Risk of Recurrence https://ClinicalTrials.gov/show/NCT03558503 Active, not recruiting UroGen Pharma Ltd. 2019-12-04
NCT03557918 Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT03557918 Recruiting Hoosier Cancer Research Network 2020-07-31
NCT03549715 NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03549715 Recruiting Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie 2023-11-30
NCT03534804 Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03534804 Recruiting University of Utah 2023-09-30
NCT03523572 Trastuzumab Deruxtecan With Nivolumab in Advanced Breast and Urothelial Cancer https://ClinicalTrials.gov/show/NCT03523572 Recruiting Daiichi Sankyo, Inc. 2020-09-30
NCT03520231 Study Comparing Denosumab With Standard Treatment in Urothelial Cancer Patients With Bone Metastases https://ClinicalTrials.gov/show/NCT03520231 Recruiting University Health Network, Toronto 2019-12-01
NCT03513952 Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03513952 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT03511391 CHEckpoint Inhibition in Combination With an Immunoboost of External Body Radiotherapy in Solid Tumors https://ClinicalTrials.gov/show/NCT03511391 Recruiting University Hospital, Ghent 2022-02-14
NCT03507166 A Phase II Study of RC48-ADC in Subjects With HER2 Positive Metastatic or Unresectable Urothelial Cancer https://ClinicalTrials.gov/show/NCT03507166 Completed RemeGen 2018-10-29
NCT03486197 Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03486197 Recruiting University of Washington 2022-11-01
NCT03473756 Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03473756 Recruiting Bayer 2024-03-18
NCT03473743 A Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Erdafitinib Plus JNJ-63723283 (Cetrelimab), an Anti-PD-1 Monoclonal Antibody, in Participants With Metastatic or Locally Advanced Urothelial Cancer With Selected FGFR Gene Alterations https://ClinicalTrials.gov/show/NCT03473743 Recruiting Janssen Research & Development, LLC 2021-06-17
NCT03473730 Daratumumab in Treating Patients With Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer https://ClinicalTrials.gov/show/NCT03473730 Recruiting M.D. Anderson Cancer Center 2021-12-31
NCT03421652 Nivolumab and Radiation Therapy in Treating Patients With Localized/Locally Advanced Urothelial Bladder Cancer Ineligible for Chemotherapy https://ClinicalTrials.gov/show/NCT03421652 Recruiting Barbara Ann Karmanos Cancer Institute 2021-01-31
NCT01261728 Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy in Patients With High-Grade Upper Tract Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT01261728 Active, not recruiting Memorial Sloan Kettering Cancer Center 2021-12-31
NCT01225887 Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer https://ClinicalTrials.gov/show/NCT01225887 Completed Gynecologic Oncology Group 2016-01-31
NCT01191892 Carboplatin and Gemcitabine Hydrochloride With or Without Vandetanib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urinary Tract Cancer https://ClinicalTrials.gov/show/NCT01191892 Completed Cardiff University 2015-12-31
NCT01097746 First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01097746 Active, not recruiting M.D. Anderson Cancer Center 2020-04-30
NCT01093066 Prospective Multicentric Evaluation of a Bladder Preservation Strategy https://ClinicalTrials.gov/show/NCT01093066 Active, not recruiting Centre Hospitalier Universitaire de Saint Etienne 2022-12-31
NCT01090466 Gemcitabine Hydrochloride, Cisplatin, and Temsirolimus as First-Line Therapy in Treating Patients With Locally Advanced and/or Metastatic Transitional Cell Cancer of the Urothelium https://ClinicalTrials.gov/show/NCT01090466 Completed Cardiff University 2010-01-31
NCT01089088 Gemcitabine Hydrochloride, Cisplatin, and Sunitinib Malate as First-Line Therapy in Treating Patients With Locally Advanced And/or Metastatic Transitional Cell Carcinoma of the Urothelium (SUCCINCT) https://ClinicalTrials.gov/show/NCT01089088 Completed Cardiff University 2014-10-31
NCT01074411 Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT01074411 Completed National Cancer Institute (NCI) 2014-04-04
NCT01031875 Pazopanib Hydrochloride in Treating Patients With Metastatic Urethral Cancer or Bladder Cancer That Has Relapsed or Not Responded to Treatment https://ClinicalTrials.gov/show/NCT01031875 Completed National Cancer Institute (NCI) 2011-12-31
NCT01031420 Dose Dense MVAC for Muscle Invasive Bladder Cancer https://ClinicalTrials.gov/show/NCT01031420 Completed Fox Chase Cancer Center 2013-07-19
NCT00989651 Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00989651 Active, not recruiting National Cancer Institute (NCI) 2020-09-01
NCT00963859 Robotic-Assisted Laparoscopic Extended Pelvic Lymph Node Dissection for Transitional Cell Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT00963859 Completed M.D. Anderson Cancer Center 2011-06-30
NCT00942331 Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer https://ClinicalTrials.gov/show/NCT00942331 Active, not recruiting National Cancer Institute (NCI) 2018-11-02
NCT00888173 Brivanib Alaninate in Treating Patients With Recurrent or Persistent Endometrial Cancer https://ClinicalTrials.gov/show/NCT00888173 Completed Gynecologic Oncology Group 2016-07-16
NCT00880334 Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC https://ClinicalTrials.gov/show/NCT00880334 Completed Dana-Farber Cancer Institute 2013-12-31
NCT03794102 Water Versus Saline as Irrigation Fluid for Ureteroscopy https://ClinicalTrials.gov/show/NCT03794102 Completed Emory University 2017-12-22
NCT02795156 Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations https://ClinicalTrials.gov/show/NCT02795156 Recruiting SCRI Development Innovations, LLC 2020-12-01
NCT02599324 A Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary Tumors https://ClinicalTrials.gov/show/NCT02599324 Recruiting Pharmacyclics LLC. 2022-04-30
NCT00794950 Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT00794950 Completed University of Michigan 2016-08-22
NCT04003610 Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) https://ClinicalTrials.gov/show/NCT04003610 Recruiting Incyte Corporation 2022-11-30
NCT03636256 Evaluation of NanoDoce® in Participants With Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03636256 Recruiting NanOlogy, LLC 2020-11-30
NCT00808639 Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT00808639 Completed Dana-Farber Cancer Institute 2013-12-31
NCT01828736 Efficacy of Combination of Trastuzumab to Gemcitabine - Platinum Advanced or Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT01828736 Completed Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie 2010-02-23
NCT00805129 Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium https://ClinicalTrials.gov/show/NCT00805129 Active, not recruiting Memorial Sloan Kettering Cancer Center 2020-12-31
NCT04073602 A Study of RC48-ADC in Subjects With HER2-negative Locally Advanced or Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT04073602 Recruiting RemeGen 2020-06-30
NCT03062059 The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence https://ClinicalTrials.gov/show/NCT03062059 Recruiting National Cancer Center, Korea 2021-12-31
NCT02581982 Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT02581982 Active, not recruiting Wake Forest University Health Sciences 2020-12-31
NCT03898180 Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) https://ClinicalTrials.gov/show/NCT03898180 Recruiting Merck Sharp & Dohme Corp. 2022-12-30
NCT03866382 Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors https://ClinicalTrials.gov/show/NCT03866382 Recruiting National Cancer Institute (NCI) 2023-02-28
NCT02365766 Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects https://ClinicalTrials.gov/show/NCT02365766 Active, not recruiting Hoosier Cancer Research Network 2020-07-31
NCT03244384 Testing MK-3475 (Pembrolizumab) After Surgery for Localized Muscle-Invasive Bladder Cancer and Locally Advanced Urothelial Cancer https://ClinicalTrials.gov/show/NCT03244384 Recruiting National Cancer Institute (NCI) 2025-06-01
NCT02834013 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors https://ClinicalTrials.gov/show/NCT02834013 Recruiting National Cancer Institute (NCI) 2021-08-31
NCT04432857 AN0025 and Pembrolizumab Combination in Advanced Solid Tumors https://ClinicalTrials.gov/show/NCT04432857 Recruiting Adlai Nortye Biopharma Co., Ltd. 2022-12-31
NCT02178241 Gemcitabine Hydrochloride and Eribulin Mesylate in Treating Patients With Bladder Cancer That is Advanced or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT02178241 Completed National Cancer Institute (NCI) 2019-03-18
NCT04129606 Bladder Perforation Post-TURBT: Definition, Incidence and Natural HistoryStudy https://ClinicalTrials.gov/show/NCT04129606 Active, not recruiting Mansoura University 2021-07-01
NCT03529890 Radio-Immunotherapy Before Cystectomy in Locally Advanced Urothelial Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT03529890 Recruiting Technische Universität München 2022-02-28
NCT00888615 Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00888615 Completed Gynecologic Oncology Group 2011-09-01
NCT00792025 Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer https://ClinicalTrials.gov/show/NCT00792025 Completed National Cancer Institute (NCI) 2011-05-31
NCT00790426 Phase II Study of TKI258 in Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT00790426 Completed Novartis 2012-04-30
NCT00749892 Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer https://ClinicalTrials.gov/show/NCT00749892 Completed M.D. Anderson Cancer Center 2019-06-30
NCT00734994 Mitomycin C With Hyperthermia and Intravesical Mitomycin C to Treat Recurrent Bladder Cancer https://ClinicalTrials.gov/show/NCT00734994 Completed Duke University 2011-02-28
NCT00722553 Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder https://ClinicalTrials.gov/show/NCT00722553 Completed Acrotech Biopharma LLC 2011-04-30
NCT00719303 Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer https://ClinicalTrials.gov/show/NCT00719303 Recruiting Gynecologic Oncology Group 2020-12-31
NCT00714025 A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy https://ClinicalTrials.gov/show/NCT00714025 Completed Cliniques universitaires Saint-Luc- Université Catholique de Louvain 2009-04-30
NCT00710970 Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment https://ClinicalTrials.gov/show/NCT00710970 Completed Baylor College of Medicine 2011-12-31
NCT00706641 Neoadjuvant Dasatinib and Radical Cystectomy for Transitional Cell Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT00706641 Completed Hoosier Cancer Research Network 2012-12-31
NCT00694798 Study of Mycobacterium w in BCG Refractory Superficial Transitional Cell Carcinoma of Bladder https://ClinicalTrials.gov/show/NCT00694798 Completed Cadila Pharnmaceuticals 2011-07-31
NCT00683059 Single Agent Abraxane as Second Line Therapy in Bladder Cancer https://ClinicalTrials.gov/show/NCT00683059 Completed Sunnybrook Health Sciences Centre 2012-06-30
NCT00633789 Phase II Study of Brivanib (BMS-582664) to Treat Multiple Tumor Types https://ClinicalTrials.gov/show/NCT00633789 Completed Bristol-Myers Squibb 2012-02-29
NCT00623831 A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen https://ClinicalTrials.gov/show/NCT00623831 Completed Ludwig Institute for Cancer Research 2012-05-31
NCT00623064 Lapatinib, Cisplatin, Gemcitabine as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT00623064 Completed European Organisation for Research and Treatment of Cancer - EORTC 2012-06-30
NCT00588666 Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT00588666 Completed Memorial Sloan Kettering Cancer Center 2011-12-31
NCT00539773 Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder https://ClinicalTrials.gov/show/NCT00539773 Completed King Faisal Specialist Hospital & Research Center 2013-09-30
NCT00536588 A Safety and Tolerability Study of SCH 721015 in Patients With Transitional Cell Carcinoma of the Bladder (Study P03816) https://ClinicalTrials.gov/show/NCT00536588 Completed Merck Sharp & Dohme Corp. 2009-08-31
NCT01167712 Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT01167712 Active, not recruiting National Cancer Institute (NCI) 2015-12-01
NCT00478361 Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function https://ClinicalTrials.gov/show/NCT00478361 Completed M.D. Anderson Cancer Center 2015-06-30
NCT00471536 Pazopanib in Treating Patients With Metastatic Urothelial Cancer https://ClinicalTrials.gov/show/NCT00471536 Completed National Cancer Institute (NCI) 2010-07-31
NCT00462488 Study of Vicinium for Treating Patients With Non-Invasive Urothelial Carcinoma In Situ https://ClinicalTrials.gov/show/NCT00462488 Completed Viventia Bio 2009-10-31
NCT00407485 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium https://ClinicalTrials.gov/show/NCT00407485 Completed National Cancer Institute (NCI) 2010-04-30
NCT00397488 Sunitinib in Treating Patients With Progressive Metastatic Transitional Cell Cancer of the Urothelium https://ClinicalTrials.gov/show/NCT00397488 Completed Memorial Sloan Kettering Cancer Center 2012-02-29
NCT00389155 First-Line Treatment of Advanced Bladder Cancer Randomized vs. Gemcitabine ± Vinflunine in Patients Ineligible to Receive Cisplatin-Based Therapy https://ClinicalTrials.gov/show/NCT00389155 Completed Bristol-Myers Squibb 2008-01-31
NCT00365157 Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction https://ClinicalTrials.gov/show/NCT00365157 Active, not recruiting National Cancer Institute (NCI) 2020-12-31
NCT00362713 Study of Neoadjuvant Ipilimumab in Patients With Urothelial Carcinoma Undergoing Surgical Resection https://ClinicalTrials.gov/show/NCT00362713 Completed Bristol-Myers Squibb 2009-10-31
NCT00343356 Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of Bladder https://ClinicalTrials.gov/show/NCT00343356 Completed LanZhou University NA
NCT00330499 Efficacy Study of Adding Chemotherapy to Radiotherapy for Treating Bladder Cancer. https://ClinicalTrials.gov/show/NCT00330499 Completed Trans-Tasman Radiation Oncology Group (TROG) 2010-02-28
NCT00315237 Phase III Trial of Vinflunine Plus Best Supportive Care vs. Best Supportive Care in Patients With Transitional Cell Carcinoma (TCC) of the Urothelial Tract https://ClinicalTrials.gov/show/NCT00315237 Completed Bristol-Myers Squibb 2008-01-31
NCT00310011 Gemcitabine, Paclitaxel, and Cisplatin in Treating Patients With Advanced Cancer of the Urothelium https://ClinicalTrials.gov/show/NCT00310011 Completed Wake Forest University Health Sciences 2005-10-31
NCT00262847 Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00262847 Completed National Cancer Institute (NCI) 2010-11-30
NCT00238420 Paclitaxel and Radiation Therapy With or Without Trastuzumab in Treating Patients Who Have Undergone Surgery for Bladder Cancer https://ClinicalTrials.gov/show/NCT00238420 Active, not recruiting National Cancer Institute (NCI) 2014-02-05
NCT00191971 2nd Line Gemcitabine Monotherapy for Transitional Cell Carcinoma of Urothelium (TCC) After CDDP Regimen https://ClinicalTrials.gov/show/NCT00191971 Completed Eli Lilly and Company NA
NCT00173862 Gemcitabine and Ifosfamide As a Second-Line Systemic Chemotherapy for Cisplatin -Failed Advanced TCC https://ClinicalTrials.gov/show/NCT00173862 Completed National Taiwan University Hospital NA
NCT00154687 Weekly TP-HDFL in the Treatment of Advanced TCC https://ClinicalTrials.gov/show/NCT00154687 Completed National Taiwan University Hospital NA
NCT00112671 Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract https://ClinicalTrials.gov/show/NCT00112671 Completed National Cancer Institute (NCI) 2010-05-31
NCT00108745 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer https://ClinicalTrials.gov/show/NCT00108745 Active, not recruiting Gynecologic Oncology Group 2022-01-01
NCT00101842 Gemcitabine and Platinol Followed by Pemetrexed and Gemcitabine in Patients With Advanced or Metastatic Bladder Cancer https://ClinicalTrials.gov/show/NCT00101842 Completed Eli Lilly and Company NA
NCT00101608 Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium https://ClinicalTrials.gov/show/NCT00101608 Completed Bristol-Myers Squibb 2007-04-30
NCT00002914 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract https://ClinicalTrials.gov/show/NCT00002914 Completed Eastern Cooperative Oncology Group 2001-06-30
NCT00003175 Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer https://ClinicalTrials.gov/show/NCT00003175 Completed National Cancer Institute (NCI) NA
NCT00003133 Combination Chemotherapy Following Surgery in Treating Patients With Advanced Bladder Cancer https://ClinicalTrials.gov/show/NCT00003133 Completed Memorial Sloan Kettering Cancer Center 2003-01-31
NCT00003376 Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium https://ClinicalTrials.gov/show/NCT00003376 Completed Eastern Cooperative Oncology Group 2005-09-30
NCT00080795 Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium https://ClinicalTrials.gov/show/NCT00080795 Completed M.D. Anderson Cancer Center 2006-05-31
NCT00006376 R115777 in Treating Patients With Advanced Bladder Cancer https://ClinicalTrials.gov/show/NCT00006376 Completed National Cancer Institute (NCI) NA
NCT00006026 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract https://ClinicalTrials.gov/show/NCT00006026 Completed European Organisation for Research and Treatment of Cancer - EORTC 2001-10-31
NCT00004223 Docetaxel and Gemcitabine in Treating Patients With Progressive Regional or Metastatic Bladder Cancer https://ClinicalTrials.gov/show/NCT00004223 Completed Eastern Cooperative Oncology Group 2002-10-31
NCT00077688 TOCOSOL(TM) Paclitaxel in Metastatic or Locally Advanced Unresectable Transitional Cell Carcinoma of the Urothelium https://ClinicalTrials.gov/show/NCT00077688 Completed Achieve Life Sciences NA
NCT00004203 Oxaliplatin in Treating Patients With Metastatic Bladder Cancer https://ClinicalTrials.gov/show/NCT00004203 Completed University of Chicago 2002-02-28
NCT00009867 Arsenic Trioxide in Treating Patients With Urothelial Cancer https://ClinicalTrials.gov/show/NCT00009867 Completed National Cancer Institute (NCI) 2004-06-30
NCT00003167 Gene Therapy in Treating Patients With Advanced Bladder Cancer https://ClinicalTrials.gov/show/NCT00003167 Completed National Cancer Institute (NCI) 2002-12-31
NCT00072150 Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma https://ClinicalTrials.gov/show/NCT00072150 Completed National Cancer Institute (NCI) 2006-03-31
NCT00004074 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu https://ClinicalTrials.gov/show/NCT00004074 Completed National Cancer Institute (NCI) 2009-02-28
NCT00014144 S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract https://ClinicalTrials.gov/show/NCT00014144 Completed Southwest Oncology Group 2003-05-31
NCT00021099 Ixabepilone in Treating Patients With Advanced Urinary Tract Cancer https://ClinicalTrials.gov/show/NCT00021099 Completed National Cancer Institute (NCI) 2007-08-31
NCT00066612 S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy https://ClinicalTrials.gov/show/NCT00066612 Completed Southwest Oncology Group 2007-08-31
NCT00066352 Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter https://ClinicalTrials.gov/show/NCT00066352 Completed University Health Network, Toronto 2003-09-30
NCT00053209 Pemetrexed Disodium and Gemcitabine in Treating Patients With Advanced Cancer of the Urothelium https://ClinicalTrials.gov/show/NCT00053209 Completed Eastern Cooperative Oncology Group 2007-09-30
NCT00045630 S0219, Combination Chemotherapy Followed By Observation or Surgery in Patients With Stage II or Stage III Cancer of the Urothelium https://ClinicalTrials.gov/show/NCT00045630 Completed Southwest Oncology Group 2008-05-31
NCT00041106 Gefitinib Plus Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Bladder Cancer https://ClinicalTrials.gov/show/NCT00041106 Completed National Cancer Institute (NCI) 2007-07-31
NCT00028860 Combination Chemotherapy Following Surgery in Treating Patients With Urinary Tract Cancer https://ClinicalTrials.gov/show/NCT00028860 Completed National Cancer Institute (NCI) NA
NCT00028756 Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium https://ClinicalTrials.gov/show/NCT00028756 Completed European Organisation for Research and Treatment of Cancer - EORTC 2014-01-31
NCT00022191 Cisplatin Plus Gemcitabine With or Without Paclitaxel in Treating Patients With Stage IV Urinary Tract Cancer https://ClinicalTrials.gov/show/NCT00022191 Completed European Organisation for Research and Treatment of Cancer - EORTC 2004-06-30
NCT00014274 Combination Chemotherapy in Treating Patients With Transitional Cell Cancer of the Urothelium https://ClinicalTrials.gov/show/NCT00014274 Completed European Organisation for Research and Treatment of Cancer - EORTC 2008-03-31
NCT00006351 SCH 66336 Plus Gemcitabine in Treating Patients With Advanced Cancer of the Urinary Tract https://ClinicalTrials.gov/show/NCT00006351 Completed European Organisation for Research and Treatment of Cancer - EORTC 2001-12-31
NCT00005831 Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer https://ClinicalTrials.gov/show/NCT00005831 Completed National Cancer Institute (NCI) 2004-08-31
NCT00005644 Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium and Decreased Kidney Function https://ClinicalTrials.gov/show/NCT00005644 Completed Eastern Cooperative Oncology Group 2003-02-28
NCT00003342 Combination Chemotherapy in Treating Patients With Advanced Bladder or Kidney Cancer https://ClinicalTrials.gov/show/NCT00003342 Completed Memorial Sloan Kettering Cancer Center 2007-07-31
NCT00001381 A Phase I Trial Using Suramin to Treat Superficial Transitional Cell Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT00001381 Completed National Institutes of Health Clinical Center (CC) NA
NCT00035061 A Phase 2 Trial of ALIMTA (Pemetrexed) in Locally Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium https://ClinicalTrials.gov/show/NCT00035061 Completed Eli Lilly and Company NA
NCT00034593 A Phase 2 Trial of ALIMTA (Pemetrexed) Plus Gemcitabine in Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium https://ClinicalTrials.gov/show/NCT00034593 Completed Eli Lilly and Company NA
NCT00003105 Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer https://ClinicalTrials.gov/show/NCT00003105 Completed Memorial Sloan Kettering Cancer Center 2004-08-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03782207 A Study Investigating the Outcomes and Safety of Atezolizumab Under Real-World Conditions in Patients Treated in Routine Clinical Practice https://ClinicalTrials.gov/show/NCT03782207 Recruiting Hoffmann-La Roche 2024-12-19
NCT03291028 Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03291028 Recruiting Fox Chase Cancer Center 2020-12-31
NCT03256877 Detecting Transitional Cell Carcinoma From Haematuria https://ClinicalTrials.gov/show/NCT03256877 Completed Hull University Teaching Hospitals NHS Trust 2018-05-28
NCT03013920 CLE Characteristics of Upper Urinary Tract Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03013920 Completed Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 2018-04-30
NCT03013894 Confocal Laser Endomicroscopy in the Lower Urinary Tract https://ClinicalTrials.gov/show/NCT03013894 Completed Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 2017-10-31
NCT03232593 A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) https://ClinicalTrials.gov/show/NCT03232593 Recruiting Hoffmann-La Roche 2023-01-11
NCT02745301 Urinary Biomarkers in the Detection of Urothelial Carcinoma of the Bladder https://ClinicalTrials.gov/show/NCT02745301 Completed Vanderbilt University Medical Center 2018-01-31
NCT02700659 The Cxbladder Monitoring Study https://ClinicalTrials.gov/show/NCT02700659 Completed Pacific Edge Limited 2016-09-23
NCT04432909 A Prospective, Multi-centre, Single-blinded Study of UroCAD for Urothelial Carcinoma Diagnosis and Follow-up https://ClinicalTrials.gov/show/NCT04432909 Recruiting Changhai Hospital 2022-01-30
NCT03998371 Application of UCAD for Diagnosing Urothelial Carcinoma. https://ClinicalTrials.gov/show/NCT03998371 Recruiting Changhai Hospital 2020-05-05
NCT03896958 The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) https://ClinicalTrials.gov/show/NCT03896958 Recruiting SpeciCare 2021-03-12
NCT03794128 A Study of Personalized Neoantigen Cancer Vaccines https://ClinicalTrials.gov/show/NCT03794128 Active, not recruiting Gritstone Oncology, Inc. 2020-01-17
NCT03677544 Predictive Factorsfor Final Pathologic Ureteral Sections https://ClinicalTrials.gov/show/NCT03677544 Completed Centre Hospitalier Universitaire, Amiens 2017-06-01
NCT03673202 The Cxbladder Rule-out of Recurrent Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03673202 Recruiting London Health Sciences Centre 2019-08-31
NCT03548688 Investigation and Detection of Urological Neoplasia in Patients Referred With Suspected Urinary Tract Cancer: https://ClinicalTrials.gov/show/NCT03548688 Completed British Urology Researchers in Surgical Training 2019-12-14
NCT01135849 B-Receptor Signaling in Cardiomyopathy https://ClinicalTrials.gov/show/NCT01135849 Completed Stanford University 2010-10-31
NCT01103544 JAVLOR® Online Non-Interventional Trial https://ClinicalTrials.gov/show/NCT01103544 Completed Pierre Fabre Pharma GmbH 2011-09-30
NCT01050504 Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer https://ClinicalTrials.gov/show/NCT01050504 Recruiting University of Washington 2021-09-01
NCT00900276 Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants https://ClinicalTrials.gov/show/NCT00900276 Completed Wake Forest University Health Sciences 2011-04-30
NCT04146064 Breathomics as Predictive Biomarker for Checkpoint Inhibitor Response https://ClinicalTrials.gov/show/NCT04146064 Recruiting University Health Network, Toronto 2024-05-31
NCT03788746 Prevalence of PD-L1 Expression in Patients With Advanced Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03788746 Recruiting AstraZeneca 2020-12-09
NCT04314245 Diagnostic Evaluation of Urine DNA Methylation/Somatic Mutation Profiling for the Detection of Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT04314245 Recruiting AnchorDx Medical Co., Ltd. 2020-08-31
NCT01395225 Lymph Node Processing Protocol for Radical Cystectomy and Pelvic Lymph Node Dissection in Bladder Cancer https://ClinicalTrials.gov/show/NCT01395225 Completed University of British Columbia 2013-04-30
NCT00612326 Feasibility Evaluation of Magnetic Resonance Imaging and Positron Emission Tomography for Bladder Cancer Diagnosis and Staging https://ClinicalTrials.gov/show/NCT00612326 Completed Memorial Sloan Kettering Cancer Center 2008-03-31
NCT00216801 Relationship of Ochratoxin A to Upper Urologic Cancers https://ClinicalTrials.gov/show/NCT00216801 Completed Lawson Health Research Institute 2007-04-30

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03280459 Evaluation of Robot-assisted Intracorporeal Urinary Reconstruction https://ClinicalTrials.gov/show/NCT03280459 Recruiting Kantonsspital Winterthur KSW 2023-06-01
NCT03544437 Feasibility and Safety of Extraperitoneal Laparoscopic Extended Retroperitoneal Lymph Node Dissection at Time of Nephroureterectomy for Upper Tract Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03544437 Recruiting RenJi Hospital 2018-12-30